Very few people need to be reminded of the constant threat of COVID-19. Now that the first vaccine has been released for emergency use, it’s time for people to do their research to find out if their medical conditions and subsequent medications will have an impact on their ability to be administered the vaccine or not. Inflammation conditions caused by psoriasis vary greatly and the concerns of comorbidities that make the virus more lethal has brought on extra concerns regarding psoriasis and acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The National Psoriasis Foundation (NPF) has issued new guidance for the more than 8 million Americans who are suffering from forms of psoriasis. With the new mRNA vaccines demonstrating roughly 95% effectiveness in preventing COVID19, and with a strong safety profile, the NPF’s new guidance recommends that psoriasis patients get the vaccine as soon as they are able to get the vaccine. And for even better news, the NPF is also recommending that psoriasis patients continue their oral or biologic psoriasis or psoriatic arthritis treatments without interruption during the immunization process.
The NPF also pointed toward a recent article from the Journal of the American Academy of Dermatology regarding psoriatic disease management during the pandemic, and noted that new statements and updates are in preparation for submission.
The National Psoriasis Foundation has a larger updated COVID-19 Task Force Guidance statements being updated as more data comes available.